SecurityERIE / Erie Indemnity Co.
InstitutionBank Of Montreal /can/
Shares7,986
Value $ 940,000
Related ERIEB / Erie Indemnity Co.

Bank Of Montreal /can/ reports 5.20% decrease in ownership of ERIE / Erie Indemnity Co.

April 13, 2018 - Bank Of Montreal /can/ has filed a 13F-HR form disclosing ownership of 7,986 shares of Erie Indemnity Co. (NASDAQ:ERIE) with total holdings valued at $940,000 USD as of March 31, 2018. Bank Of Montreal /can/ had filed a previous 13F-HR on January 16, 2018 disclosing 8,424 shares of Erie Indemnity Co. at a value of $1,027,000 USD. This represents a change in shares of -5.20 percent and a change in value of -8.47 percent during the quarter.

Other investors with positions similar to Bank Of Montreal /can/ include Legal & General Group Plc, Invesco Ltd., Sullivan, Bruyette, Speros & Blaney, Inc., Millennium Management Llc, Teacher Retirement System Of Texas, and Bishop & Co Investment Management, LLC.

ERIE INDEMNITY CO has declared a standard industrial code (sic) of 6411 which is the "Insurance Agents, Brokers, and Service" industry. Bank Of Montreal /can/'s top industries are "Agriculture production livestock and animal specialties" (sic 02), "Legal Services" (sic 81), and "Social Services" (sic 83).

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-03-31 13F-HR ERIE INDTY CL A 29530P102 119.81 7,986 -5.20 940 -8.47 -52 -35 -3.36
2017-12-31 13F-HR ERIE INDTY CL A 29530P102 121.32 8,424 20.77 1,027 21.97 176 9 1.09
2017-09-30 13F-HR ERIE INDTY CL A 29530P102 122.91 6,975 2.66 842 -0.94 22 -30 -3.56
2017-06-30 13F-HR ERIE INDTY CL A 29530P102 123.85 6,794 7.19 850 9.40 56 17 2.13
2017-03-31 13F-HR ERIE INDTY CL A 29530P102 114.92 6,338 -9.00 777 4.02 -72 102 13.66
2016-12-31 13F-HR ERIE INDTY CL A 29530P102 104.64 6,965 -9.24 747 -4.60 -74 38 4.88
2016-09-30 13F-HR *ERIE INDTY CL A 29530P102 100.68 7,674 0.03 783 2.76 0 21 2.73
2016-06-30 13F-HR *ERIE INDTY CL A 29530P102 96.18 7,672 -54.10 762 -51.00 -870 77 4.93
2016-03-31 13F-HR *ERIE INDTY CL A 29530P102 94.35 16,714 3.83 1,555 0.97 58 -43 -2.80
2015-12-31 13F-HR *ERIE INDTY CL A 29530P102 89.29 16,098 63.17 1,540 88.26 556 166 20.24
2015-09-30 13F-HR ERIE INDTY CL A 29530P102 82.49 9,866 -55.73 818 -55.28 -1,025 14 0.75
2015-06-30 13F-HR ERIE INDTY CL A 29530P102 84.65 22,288 -15.53 1,829 -20.55 -347 -126 -5.48
2015-03-31 13F-HR ERIE INDTY CL A 29530P102 89.02 26,385 11.90 2,302 7.52 250 -89 -4.15
2014-12-31 13F-HR ERIE INDTY CL A 29530P102 83.30 23,579 3.01 2,141 23.40 57 349 20.09
2014-09-30 13F-HR ERIE INDTY CL A 29530P102 75.54 22,889 28.69 1,735 29.57 385 11 0.78
2014-06-30 13F-HR ERIE INDTY CL A 29530P102 72.51 17,786 -5.39 1,339 2.14 -74 102 7.74
2014-03-31 13F-HR ERIE INDTY CL A 29530P102 18,800 1,311

Related SEC Filings

ERIE / Erie Indemnity Co. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-08 sec.gov
erieindemnityco.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Erie Indemnity Co     Title of Class of Securities:  Common Stock     CUSIP Number:  29530P102     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule

ERIE / Erie Indemnity Co. / VANGUARD GROUP INC - 3G (Passive Investment)

2018-02-08 sec.gov
erieindemnityco.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 0 )*       Name of issuer:  Erie Indemnity Co     Title of Class of Securities:  Common Stock     CUSIP Number:  29530P102     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   (X) Rule

ERIE / Erie Indemnity Co. / PNC FINANCIAL SERVICES GROUP, INC. - SC 13G/A (Passive Investment)

2018-02-02 sec.gov
SC 13G/A     SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G/A (RULE 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (“ACT”) (AMENDMENT NO. 9)     Erie Indemnity Company (Name of Issuer) Class A Common Stock (Title of Class of Securities) 29530P102 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Sta

ERIE / Erie Indemnity Co. / PNC FINANCIAL SERVICES GROUP, INC. - SC 13G/A (Passive Investment)

2018-02-02 sec.gov
SC 13G/A     SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G/A (RULE 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (“ACT”) (AMENDMENT NO. 9)     Erie Indemnity Company (Name of Issuer) Class A Common Stock (Title of Class of Securities) 29530P102 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Sta

Erie Indemnity SC 13G/A (Passive Acquisition of More Than 5% of Shares)

2017-02-03 sec.gov
SC 13G/A     SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G/A (RULE 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (“ACT”) (AMENDMENT NO. 8)     Erie Indemnity Company (Name of Issuer) Class A Common Stock (Title of Class of Securities) 29530P102 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Sta

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...



CUSIP: 29530P102